Trials / Completed
CompletedNCT03226769
Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease
Prospective, Open-Label, Randomized, Proof of Concept Study Exploring Application of TrueTear™ for the Treatment of Meibomian Gland Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 22 Years
- Healthy volunteers
- Not accepted
Summary
This study will compare the safety and efficacy of TrueTear™ to standardized moist heat compress (Thermalon® Dry Eye Compress) for the treatment of Meibomian Gland Disease (MGD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | TrueTear™ | Intranasal application of TrueTear™ device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear™ per participant guide. |
| DEVICE | Thermalon Dry Eye Compress | Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions. |
Timeline
- Start date
- 2017-07-26
- Primary completion
- 2017-12-12
- Completion
- 2017-12-12
- First posted
- 2017-07-24
- Last updated
- 2020-10-30
- Results posted
- 2020-10-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03226769. Inclusion in this directory is not an endorsement.